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Background: Reports indicate that nutritional and respiratory decline occur up to four years prior to diagnosis of cystic fibrosis related diabetes
(CFRD). Our aim was to establish whether intensive nutritional intervention prevents pre-diabetic nutritional decline in an adult population with
CFRD.
Methods: 48 adult patients with CFRD were matched to 48 controls with CF, for age, gender and lung pathogen status. Nutritional and other
clinical indices were recorded at annual intervals from six years before until two years after diagnosis. Data were also analysed to examine the
impact of early and late acquisition of CFRD.
Results: No important differences in weight, height, body mass index (BMI), lung function or intravenous treatment were found between groups in
the six years prior to diagnosis, nor any significant deviation over time. In those who developed diabetes, use of overnight enteral tube feeding
(ETF) was four times as likely at the time of diagnosis, compared to controls [ETF 43.8% (CFRD) v 18.8% (CF Controls), OR 4.0, CI 1.3 to 16.4,
p=0.01]. Age at onset of CFRD played a significant role in determining the pre-diabetic clinical course. Younger diabetics with continued growth
at study onset (n=17) had a lower BMI from 2 years prior to diagnosis compared to controls [BMI 18.9 kg/m2 (CFRD) v 20.8 kg/m2 (CF
Controls), diff=1.9, CI −0.1 to 3.7 p=0.04]. The BMI of older diabetics (completed growth at study onset) was equal to that of controls
throughout.
Conclusion: Pre-diabetic nutritional decline is not inevitable in adults with CFRD, but is influenced by age of onset. In the group overall, those
with CFRD are more likely to require ETF from 2 years prior to diagnosis. Despite intensive nutritional intervention, patients who continue to
grow throughout the pre-diabetic years, show a level of nutritional decline absent in older adults.
© 2009 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Diabetes; Age; Nutritional intervention1. Introduction
Cystic fibrosis related diabetes (CFRD) is a well established
complication of cystic fibrosis (CF). The condition is present in
around 16% of the CF population, but is present in over 40% of
those over thirty years of age [1,2]. Incidence is associated with
increasing age, female gender and pancreatic insufficiency [3,4].⁎ Corresponding author. Leeds Metropolitan University, Leeds, UK.
E-mail address: H.White@leedsmet.ac.uk (H. White).
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doi:10.1016/j.jcf.2008.12.002CFRD has been linked to a decline in lung function and
nutritional status which occurs for several years prior to diag-
nosis of diabetes. Although insulin therapy leads to significant
improvement in health status it does not fully reverse the neg-
ative impact on morbidity and mortality [4–8]. Deficits in nu-
tritional status in patients with CFRD have been widely reported
and are evident even in those patients who develop diabetes in
their teenage years [4,6]. Surprisingly little is known about the
potential impact of intensive early nutritional intervention in
patients with CFRD. The major studies have focused on clinicd by Elsevier B.V. All rights reserved.
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defined. Patients' weight was often sub-optimal in the years
preceding diagnosis of diabetes and at diagnosis itself, and may
well have compounded a persistent nutritional deficit [5,6,9].
In contrast, data from the Leeds Adult CF Unit indicate no
difference between the nutritional status of patients with and
without CFRD [10], possibly due to our prolonged use of pro-
active nutritional interventions, including the use of high calorie
oral nutritional supplements and enteral tube feeding and an
established screening programme for diagnosis of CFRD.
Whilst we have shown that nutritional status can be main-
tained after diagnosis of CFRD, there is no evidence to suggest
that the rate of nutritional and clinical decline can be modified
prior to the onset of diabetes. The aim of this study was to
establish whether intensive nutritional intervention can prevent
nutritional decline prior to diagnosis of CFRD.
2. Methods
2.1. Subjects
All patients diagnosed with CFRD between 1995 and 2005
attending the regional adult cystic fibrosis unit, Leeds, UK, were
included in this case control study. At the end of December 2005,
86 of 312 (28%) patients in total, were classified as diabetic
within the clinic population. Forty eight patients fulfilled the
inclusion criteria and were matched to a control with CF, with-
out diabetes, nearest in age and of the same gender and lung
pathogen status. The genetic mutation of each subject was noted
as was the presence of meconium ileus at birth. Patients who
were pancreatic sufficient, who had steroid induced CFRD, or
gestational diabetes, and those who were diagnosed with CFRD
after solid organ transplantation, were excluded.
2.2. Diagnosis of CFRD
Diagnosis of CFRD was based on the following criteria: a
diabetic glucose tolerance test performed at a time of clinical
stability, according to defined WHO criteria [11] followed by
high pre- or post meal blood sugars requiring treatment with
insulin; or acute presentation of high pre- or post-meal blood
sugars requiring treatment with insulin.
Subjects followed our standard CF unit procedure for iden-
tification of CFRD. Patients undergo annual screening using the
oral glucose tolerance test (OGTT) and undertake serial blood
glucose monitoring where the result is classified within the dia-
betic or impaired range. The OGTT is repeated at 6 months where
blood sugar monitoring does not indicate a requirement for in-
sulin. Early re-assessment of glycaemic status is also considered
between annual reviews according to UK consensus recommen-
dations [12]. Pre and post-feed blood glucose monitoring is ini-
tiated when overnight enteral tube feeding is commenced.
2.3. Nutritional support
Nutritional support was initiated according to UK consensus
guidelines [13] and was documented for each patient. Dieteticmonitoring of patients occurred at each two-monthly out-patient
appointment and at each consultation for intravenous antibiotic
treatments. Where enteral tube feeding was initiated, this was
infused overnight only and used as an adjunct to daytime oral
nutritional intake.
2.4. Measurements
Data were collected annually from six years before diag-
nosis of CFRD to two years after diagnosis [weight (kg),
height (m), BMI (kg/m2), forced expiratory volume in 1 s
(FEV1), forced vital capacity (FVC)]. These measures were
the value at the point of diagnosis in the index case and the
mean of values at out-patient attendance at the corresponding
annual time points (±2 months). The number of days of in-
travenous antibiotic therapy was recorded as the mean number
of days of treatment from six months before to six months
after each time point. The prevalence of nutritional supple-
ment intake and of enteral tube feeding was similarly calcu-
lated. Lung transplantation (after diagnosis of CFRD) and
time of death was recorded.
Pulmonary function was assessed by means of standard spi-
rometry using a Vitalograph Compact II Spirometer (Vitalo-
graph Ltd, UK). The best measurement of three satisfactory
efforts was documented. FEV1 and FVC were compared with
reference values and reported as the percentage of the predicted
normal value.
2.5. Statistical analysis
Data that were normally distributed are set out as means
plus or minus standard deviations Data were analysed using
Stata 9 (StataCorp LP, Texas). Student's paired t-tests and
confidence intervals for paired means were used to compare
differences between groups. ANOVA (repeated measures) was
used to analyse trends over time. McNemar's test and the
paired method for calculating odds ratios were used to deter-
mine differences in oral supplement and enteral tube feed use.
Alpha was set at 0.05.
Statistical power was calculated so as to detect a differ-
ence between groups of 1.0 in BMI at the time of diagnosis,
using SD of pair wise difference as 3.28; at 80% power this
estimate suggested a total sample size of 90 (45 cases and 45
controls).
The study was approved by the Leeds (East) Research Ethics
Committee, Leeds Teaching Hospitals NHS Trust, UK.
3. Results
3.1. Patient demographics
Forty eight patients with CFRD and 48 controls were in-
cluded in the study (Table 1). At the time of diagnosis of CFRD,
83% of participants had chronic Pseudomonas aeruginosa in-
fection and 82% were homozygous for the p.Phe508del mu-
tation. Similar proportions presented with meconium ileus at
birth in the CFRD and control groups.
Table 1
Participants clinical and demographic characteristics.
CFRD CF control Significance
No. (M/F) 48(17/31) 48(17/31)
Mean age at diagnosis of
diabetes (SD) (years)
26.0(5.8) 26.1(6.2)
Lung pathogen status
Chronic P. aeruginosa 40 40
Non P aeruginosa 3 3
Burkholderia cepacia complex 2 2
MRSA 1 1
CFTR mutation
p.Phe508del homozygous 30 29
p.Phe508del heterozygous 11 10
Other/other 1 1
Unknown 6 8
Meconium ileus at birth 7 6
Baseline measures
(6 years pre-diagnosis)
Body mass index (kg/m2) 19.5 20 p=0.42
FEV1 (%) 61.2 67.5 p=0.20
FVC (%) 82.4 91.6 p=0.07
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No significant differences were observed between patients
with CFRD and controls for any nutritional parameter in the
6 years before the diagnosis of CFRD (Fig. 1). During this time
period mean weight gain was 4.8 kg (CFRD) v 4.5 kg (CF
Controls) and mean BMI increased from 19.5 kg/m2 to 20.3 kg/
m2 (CFRD) v 20.0 kg/m2 to 20.7 kg/m2 (CF Controls). ANOVA
(repeat measures) confirmed no differences between patients
with CFRD and controls before the diagnosis of CFRD (F 6,
88)=7.9, p=0.38, and no deviation between patients with
CFRD and controls over time, (F 6, 88)=0.2, p=0.98.
Two years after diagnosis, the mean BMI of patients with
CFRD (21.5 kg/m2) had increased to a little above that of
controls (20.6 kg/m2) [difference=0.95, CI −1.1 to 1.2, p=0.9].
The heights of the two groups were almost identical at all timeFig. 1. Patients who develop CFRD compared to CF controlspoints [six years pre-diagnosis of CFRD,1.61 m v 1.62 m, at
diagnosis 1.66 m v 1.66 m and two years post diagnosis 1.66 m v
1.66 m].
3.3. Oral nutritional supplements and enteral nutrition
Differences in oral nutritional supplement uptake were not
significant at any point (Fig. 2). At six years before diagnosis
oral nutritional supplement uptake was 24.4% (CFRD) v 16.3%
(controls) [OR 2.3 CI 0.6 to 10, p=0.27], declining at the time
of diagnosis of CFRD, just as uptake in CF controls reached its
maximum (18.4% v 34.7%, OR 0.4, CI 0.1 to 1.2, p=0.09).
As diagnosis of CFRD approached, the proportion of patients
receiving enteral tube feeding increased steadily (Fig. 2). The
differences from controls became significant at one year before
diagnosis (35.4% (CFRD) v 14.6% (CF Controls), OR 3.5, CI
1.1 to 14.6, p=0.03) and was greatest at the time of diagnosis
(43.8% (CFRD) v 18.8% (CF Controls), OR 4.0, CI 1.3 to 16.4,
p=0.01), when diagnosis of CFRD was shown to be four times
as likely amongst patients whowere prescribed overnight enteral
tube feeding.
Nutritional supplements were in use at study onset (6 years
pre-diagnosis), in order to maintain BMI within the normal
range, [4(CFRD) v 4(CF Control)]; or to address a BMIb19 kg/
m2 [8(CFRD) v 2(CF Control)]. Enteral tube feeding was in
place due to a previous fall in centile position [2 (CFRD) v 1
(Control)]; BMIb19 kg/m2 and referred for transplant, [1(CFRD)
v 0(Control)]; BMIb19 kg/m2 [6(CFRD) v 3(Control)].
Of those who commenced enteral tube feeding throughout the
study (11CFRD v 5 CF control), the presenting reasons were
acute weight loss with BMI of b19 kg/m2 in all cases, with the
exception of 1 control who required enteral tube feeding to
maintain a normal BMI for transplant. Mean % body weight loss
in the year preceding enteral tube feeding was 8.5% (CFRD) v
2.9% (CF Control). Enteral tube feeding resulted in a mean
weight gain of 7.0% body weight at 1 year and 9.9% at 2 years
after start of enteral tube feeding in those with CFRD, compared
to 2.5% and 7.2% in controls with CF.: nutritional status before and after diagnosis of diabetes.
Fig. 2. Patients who develop CFRD compared to CF controls: nutritional support interventions.
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There was no significant difference in FEV1 between patients
with CFRD and controls at any time point [mean FEV1 (six years
pre) 61.2% v 67.5%, diff 6.3%, CI −3.4 to 16.1, p=0.2, and
(diagnosis) 46.2% v 53.7%, diff 7.5%, CI −1.1 to 16.1,
p=0.08], nor were there any significant differences in FVC
(Fig. 3). In diabetics a significant reduction in mean FEV1 was
observed from one year pre-diagnosis to the point of diagnosis
[50.8% to 46.2%, diff=4.6% (CI 2.4 to 6.4, pb0.001)], which
stabilised on initiation of insulin therapy. There were no dif-
ferences between CFRD v controls overall (F 1, 88)=0.8,
p=0.38), nor any deviation between the groups over time (F 6,
88)=0.2, p=0.98).
3.5. Antibiotic treatment
Differences in the frequency of intravenous antibiotic treat-
ment remained non-significant between groups at all time inter-Fig. 3. Patients who develop CFRD compared to CF controvals [six years pre-diagnosis 14.7 v 15.7 days, CI −8.9 to 7.0,
p=0.8, yr 0 (diagnosis) 44 v 34.7 days, CI −6.1 to 24.6,
p=0.23. No significant deviation between CFRD and controls
was observed pre diagnosis (F 6, 73)=1.4, p=0.22.
3.6. Comparison of individuals with continued growth capacity
versus those with completed growth
A sub-analysis was performed to determine whether the
same nutritional and clinical course was followed for those who
continued to grow in the six years before diagnosis (n=17, age
at diagnosis 21.9±3.7 years) and those whose growth was com-
plete in the time period (n=31, mean age 28.3±2.8 years).
In the younger patients in whom growth continued, differ-
ences in nutritional status emerged between patients with CFRD
and their matched controls at two years pre-diagnosis [BMI
18.9 kg/m2 (CFRD) v 20.8 kg/m2 (CF Controls), diff=1.9, CI −
0.1 to 3.7 p=0.04] and persisted until insulin therapy com-
menced (Fig. 4). BMI increased from 18.3 kg/m2 to 19.6 kg/m2ls: lung function before and after diagnosis of diabetes.
Fig. 4. Impact of early and late acquisition of CFRD on nutritional status and lung function.
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same level as that of their non-diabetic controls. Those who
developed CFRD were twice as likely to require oral nutritional
supplements in the early pre-diabetic years (6 years pre-
diagnosis) [47% v 17.6% OR 2.3 CI 0.6 to 10, p=0.54], and
were four times as likely to be enterally tube fed within the year
of diagnosis (64.7% v 29.4% 0R 4.0, CI 0.4 to 38.7, p=0.11),
although this did not reach significance. In this younger age
group, FEV1 remained 2–12% below that of controls throughout
the study and declined significantly in the year prior to diag-
nosis, (46.9% to 41.5% diff=5.4, CI 1.6 to 6.5, p=0.001),
stabilising on insulin therapy. Overall, there was no significant
deviation in lung function between patients with CFRD and their
controls, during the pre-diabetic phase (F 6, 21=1.7, p=0.12),
nor were there any differences in level of antibiotic treatment.
In patients where growth was complete, there was no sig-
nificant difference in mean BMI between patients with diabetes
and their controls, throughout the pre-diabetic phase. No dif-
ferences were seen in prevalence of oral sip feed use or enteral
tube feeding; nor was there any significant reduction in lung
function at any time point or any deviation in lung function over
time (F 6, 47=0.28, p=0.9).
4. Discussion
This case control study examines the impact of intensive
nutritional intervention on the course of illness before diagnosis
of CFRD. We have shown that nutritional decline is not an
inevitable precursor to CFRD. Weight, height and BMI were
similar to that of healthy controls throughout the pre-diabetic
phase and did not decline prior to diagnosis.
These findings differ from those of the previous published
studies which demonstrate declining nutritional status prior to
diagnosis of CFRD. Lanng et al. showed a progressive decline
in nutritional indices from four years before diagnosis, while a
study by Rolon et al. reported nutritional decline six months
before diagnosis of diabetes in a younger population [5,9].Both of these studies were comparable to our own in using a
closely matched study design that accounted for age, gender and
lung pathogen status. Subjects were pancreatic insufficient, with
similar proportions of patients homozygous for p.Phe508del.
There were, however, two important differences. Our population
was significantly older and had better baseline nutritional status.
More significantly, greater weight and BMI indices in our clinic
population were associated with a high level of nutritional in-
tervention. At the onset of our study around 40% of all patients
were taking oral nutritional supplements and 25% were re-
ceiving enteral tube feeds, indicating an intense and pro-active
nutritional approach that confirms previous reports from our
clinic population [10].
Although there was a high overall prevalence of nutritional
support, differences in the level of nutritional intervention emerged
between those who developed diabetes and their controls. Dif-
ficulties in maintaining nutritional status in the early pre-diabetic
phase resulted in a greater use of oral nutritional supplements in
those with CFRD, whilst at the point of diagnosis of diabetes,
patients were significantly more likely to be receiving overnight
enteral tube feeding, when compared to their control population.
This was sufficient to prevent nutritional decline throughout the
pre-diabetic phase and emphasises the fact that more intensive
nutritional intervention is required to maintain BMI in patients
who develop CFRD. The effectiveness of enteral tube feeding was
supported by the early reversal of nutritional deficits, equating to
an increase in % body weight of around 7% and 10% at one and
two years in those with CFRD.
Despite early differences in the level of nutritional support
among the diabetic and non-diabetic groups, there was no evi-
dence that lung function was significantly different or that
greater levels of antibiotic treatment were required throughout
the pre-diabetic period. This is in agreement with previous
studies that have shown no significant difference in lung func-
tion leading up to diagnosis, but contrasts with their reports of
insidious but significant deviation between groups over the same
time period [5,9]. We hypothesise that maintaining nutritional
184 H. White et al. / Journal of Cystic Fibrosis 8 (2009) 179–185status throughout the pre-diabetic phase, may prevent the pre-
viously reported decline in lung function. Several studies have
confirmed a strong relationship between lung function and nu-
tritional status [14–16].
The greater intensity of nutritional support required to main-
tain nutritional status in the pre-diabetic group might suggest that
nutritional intervention itself is a causative factor for diabetes.
Milla et al. have shown that in a population with advanced lung
disease (FEV1b40%), oral nutritional supplement intake can in-
crease glucose excursion and insulin secretion [17]. They con-
cluded that greater hyperglycaemia and higher glucose excursion
after oral supplements were directly related to the carbohydrate
content of oral supplements used, although no studies have directly
related oral nutritional supplements to diabetes onset. The nature
of the present study, precludes any causative relationship being
shown, but requires further investigation.
A number of reports have proposed that CFRD is associated
with enteral tube feeding; the incidence of diabetes ranging from
5%–50%within a one to two year follow-up period among tube-
fed patients [18–21]. Enteral tube feeding prevalence at diag-
nosis of CFRD was 44% in our study which is consistent with
previous research. Initiation of enteral tube feeding remains
justified because of its effectiveness in producing weight gain in
the short and longer term [18–21] and its impact on reducing
malnutrition; itself an important independent predictor of mor-
tality in CF [22].
Reversal of clinical and nutritional decline with insulin treat-
ment is well documented [9,23,24], as are significant improve-
ments in fat mass and percentage body fat at six months post-
insulin therapy [25]. In line with these studies, and despite no
significant deviation in nutritional wellbeing from controls,
subtle sub-clinical deficiencies were present and were corrected
with insulin therapy. We observed similar trends of 6% im-
provement in BMI and stabilisation in lung function after two
years of insulin.
These improvements were especially striking in younger
patients who had not completed their growth at the point of
inclusion in the study. Their BMI remained 5–11% below that
of their controls in the years preceding diagnosis but improved
to around 1% with insulin therapy. These differences were not
observed in an older group who had completed their growth
by the time they were included in the study. Their nutritional
status was the same as that of their control population through-
out. Those who develop diabetes during adolescence and early
adulthood appear to have a different pre-diabetic course.
This is not an unexpected finding. Younger subjects were
approximately 16 years of age at entry; a period when growth
and weight gain are continuing to increase. Pubertal growth
spurts and the stress placed upon the body during this time might
be expected to affect diabetics and controls equally before onset
of diagnosis. We observed no differences in growth between
CFRD and controls in this younger age group in the early pre-
diabetic years, but did observe significantly poorer weight gain
resulting in a lower BMI from two years before diagnosis.
Younger diabetics are simply thinner and less well nourished
than their controls from two years before diabetes onset. This is
in agreement with epidemiological data which have shown thatthose who develop diabetes at an earlier stage (15–19 years)
have greater nutritional compromise [6].
The effect of insulin therapy in improving these nutritional
deficits was greater in younger adults than in the group as a
whole. It suggests either that pre-diabetes in younger adults has a
substantial impact that cannot be addressed through nutritional
intervention, or that there is poor adherence to nutritional treat-
ment or enzyme replacement therapy. Despite 65% of these
patients receiving overnight enteral tube-feeding at the time of
diagnosis, nutritional deficits remained. Nutritional compromise
(BMIb19 kg/m2) throughout the mid teenage years was evident
in this group of patients.
Poorer nutritional status of younger adults in the pre-diabetic
years may also reflect a greater level of impaired glucose tole-
rance in this age group. Our recording of overt diabetes alone in
this current study, did not allow us to assess the presence of
impaired glucose tolerance and its nutritional impact. Glucose
tolerance abnormalities have been reported in 50% of patients
with an unsatisfactory nutritional status as opposed to 15% in
those who have not [26]. These differences suggest that ab-
normal glucose metabolism may have a considerable role in
determining clinical course in this age group and requires more
detailed assessment in our patients. Continuous subcutaneous
blood glucosemonitoring was not undertaken in this study, but is
an important factor to consider in the future, particularly in
younger adults with unexplained weight deficits.
In conclusion this study has shown that nutritional decline
before the diagnosis of CFRD, is not inevitable, although ado-
lescence is still associated with deteriorating nutritional status.
Response to insulin treatment shows a powerful, insulin induced
anabolic effect. Nutritional intervention is important in main-
taining nutritional status in the population with CFRD overall,
but cannot prevent weight loss in younger adults. Patients who
develop CFRD are significantly more likely to receive overnight
enteral tube feed within the year of diagnosis than controls,
highlighting a potential causal relationship that requires further
investigation. The impact of oral supplement and enteral feed
composition, impaired glucose tolerance, adherence to treatment
are all areas that may impact on diabetes outcome. Future work
is needed to clarify their effect on nutritional status and in
particular the impact of nutritional repletion on glucose meta-
bolism and body composition in the pre-diabetic phase.
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